I. Hepatitis B patients who can be considered pregnant 1. Women suffering from acute hepatitis B can be cured within a few months after proper treatment and reasonable recuperation. When all indicators are normal, then after a period of recuperation, when the strength is fully recovered, you can consider pregnancy. 2, chronic hepatitis B patients should first find out the severity of their disease, and then decide whether to get pregnant. 3.For pregnant women with high viral load and abnormal liver function, pregnancy may be difficult to continue without proper treatment, and antiviral treatment may be recommended for such cases; 4.Patients with only hepatitis B virus carrier but not high viral load, and ultrasound examination does not suggest cirrhosis, pregnancy can be considered. 5. Pregnant women with very high viral load but stable disease and normal liver function should try to avoid medication in the early stages of pregnancy when all organs of the embryo are developing. Second, temporarily can not be pregnant hepatitis B patients 1, if the patient’s hepatitis B inflammation is in the active stage, check the liver function abnormal, self-conscious fatigue, loss of appetite, abdominal distension, etc., this time should avoid pregnancy, liver inflammation active stage hard pregnancy, will increase the body burden, but easily lead to heavy hepatitis, endangering the life of pregnant women. Conversely, it is also not conducive to the development and growth of the fetus. Therefore, patients with active hepatitis B should first receive regular treatment, including antiviral and immunomodulatory therapy. It is in the interest of both mother and child to wait until the liver function is normalized and the viral replication index is negative or the replication capacity is reduced before pregnancy. If ultrasound examination reveals that hepatitis has progressed to the level of cirrhosis, it is best not to get pregnant. For patients with active hepatitis, after treatment, the condition is stable and the liver function is normal for more than six months, it is safer to get pregnant. 2, 2010 new version of the guidelines pointed out: female chronic hepatitis B patients of childbearing age, if there are indications for treatment, those who are not pregnant can apply interferon or nucleoside (acid) analog therapy, and during the treatment should take reliable measures to contraception. In patients who become pregnant during oral antiviral therapy, if lamivudine or other pregnancy class B drugs (telbivudine or tenofovir) are administered, treatment may continue with adequate notification of the risks, weighing of the pros and cons, and signed informed consent by the patient. If hepatitis B develops during pregnancy, antiviral therapy may be given depending on the extent of the disease, and treatment with lamivudine, telbivudine or tenofovir may be continued with adequate information about the risks, weighing the pros and cons, and with the patient’s signed informed consent. Once pregnant, hepatitis B patients should terminate the use of various hepatotoxic drugs, such as antibiotics, anti-tuberculosis drugs, drugs for diabetes, etc.; Fourth, how to perform mother-to-child blockade: 1. The new 2010 edition of the guidelines states that: the blockage rate of mother-to-child transmission by hepatitis B vaccine alone is 87.8%. For newborns of HBsAg-positive mothers, hepatitis B immunoglobulin (HBIG) should be administered as early as possible within 24 h after birth (preferably 12 h after birth) at a dose of ≥100 IU, along with 10 μg of recombinant yeast or 20 μg of Chinese hamster oocyte (CHO) hepatitis B vaccine at different sites, and the second and third doses of hepatitis B at 1 month and 6 months, respectively. The effectiveness of interruption of mother-to-child transmission is significantly improved by vaccination with hepatitis B vaccine at 1 and 6 months of age. Alternatively, one dose of HBIG can be given within 12 h of birth, followed by a second dose of HBIG 1 month later, and a 10 μg recombinant yeast or 20 μg CHO hepatitis B vaccine at different sites, followed by a second and third dose of hepatitis B vaccine 1 and 6 months apart, respectively. Newborns can receive breastfeeding from HBsAg-positive mothers after HBIG and hepatitis B vaccination within 12 h of birth. 2. In terms of mother-to-child interruption, there is no information to prove the superiority of cesarean delivery over natural delivery. For children born to HBV-DNA-positive mothers, although the guidelines recommend that breastfeeding is acceptable after blockade, it is difficult to determine the amount of virus unless the HBV-DNA in breast milk is very tested, and breastfeeding is generally not advocated. 3, pregnant women do not need to inject high-valence immunoglobulin: the application of hepatitis B immunoglobulin in pregnant women can lead to the production of HBV immune escape strains, and if the immune escape strains spread in the population will affect the preventive effect of hepatitis B vaccine. Administration of hepatitis B immunoglobulin to HBsAg-positive mothers may also result in the formation of antigen-antibody immune complexes, which are potentially dangerous to the body. In addition, the liver of a pregnant woman has not been removed, HBV is still replicating in the liver, and the dose of hepatitis B immunoglobulin is so low that it is unlikely to have the effect of blocking mother-to-child transmission of HBV. If HBsAg-positive pregnant women were given hepatitis B immunoglobulin to reduce HBV levels in the blood, then this method would have been used clinically for chronic hepatitis B for a long time, but this is not the case.